Narrative Review and Update on Biologic and Small Molecule Drugs for Hidradenitis Suppurativa: An Entity With a Promising Future

被引：0

作者：

Mansilla-Polo, M. ^{[1
,2
]}

Escutia-Munoz, B. ^{[1
,2
]}

Botella-Estrada, R. ^{[1
,2
,3
]}

机构：

[1] Hosp Univ & Politecn La Fe, Departmento Dermatol, Valencia, Spain

[2] Inst Invest Sanitaria IIS La Fe, Valencia, Spain

[3] Univ Valencia, Valencia, Spain

来源：

ACTAS DERMO-SIFILIOGRAFICAS | 2023年 / 114卷 / 09期

关键词：

Hidradenitis suppurativa; Biologics; Small molecule inhibitors; OPEN-LABEL; EFFICACY; SAFETY; ADALIMUMAB; MODERATE; THERAPY; DISEASE; SKIN; SECUKINUMAB; MULTICENTER;

D O I：

10.1016/j.ad.2023.08.001

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Hidradenitis suppurativa (HS) is a chronic inflammatory entity characterized by the appearance of multiple nodules, abscesses, and fistulas, predominantly in apocrine regions. In addition to its dermatological involvement, it is associated with multiple systemic comor-bidities. Its treatment is combined: topical pharmacological, systemic pharmacological and surgical. Regarding biologic or small molecule drugs, currently only adalimumab is approved. A narrative review of the literature on biological or small molecule drugs used in the treatment of hidradenitis suppurativa is presented. The arsenal we found is large, with multiple targets: inhibitors of tumor necrosis factor alpha (TNF-alpha), interleukin (IL)-17, IL-23, IL-1, inhibitors of the janus kinase (JAK) pathway, and multiple other drugs in study. New prospective studies and comparative trials are needed to analyze the effectiveness and safety of these treatments, in an entity with a promising future. (c) 2023 AEDV. Published by Elsevier Espana, S.L.U.

引用

页码：T772 / T783

页数：12

共 96 条

[1] Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa [J].

Aarts, Pim ;

Dudink, Koen ;

Vossen, Allard R. J. V. ;

van Straalen, Kelsey R. ;

Ardon, Christine B. ;

Prens, Errol P. ;

van der Zee, Hessel H. .

DRUGS, 2021, 81 (12) :1397-1410

[2] Long-term treatment with apremilast in hidradenitis suppurativa: A 2-year follow-up of initial responders [J].

Aarts, Pim ;

Vossen, Allard R. J. V. ;

van der Zee, Hessel H. ;

Prens, Errol P. ;

van Straalen, Kelsey R. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (01) :258-260

[3]

Abbvie, 2022, Clinical Trial Registration NCT04430855

[4]

AnaptysBio Inc, 2021, A phase 2, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of imsidolimab (ANB019) in the treatment of subjects with acne vulgaris

[5] Successful treatment of Hidradenitis Suppurativa with tofacitinib: two cases and a review of the literature [J].

Bazargan, Afsaneh Sadeghzadeh ;

Pashaei, Arezoo ;

Goodarzi, Azadeh .

OXFORD MEDICAL CASE REPORTS, 2023, 2023 (03) :89-92

[6]

Boehringer Ingelheim, 2022, Clinical Trial Registration NCT04762277

[7] New and Emerging Targeted Therapies for Hidradenitis Suppurativa [J].

Cagalj, Adela Markota ;

Marinovic, Branka ;

Mokos, Zrinka Bukvic .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (07)

[8] Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity [J].

Canoui-Poitrine, Florence ;

Revuz, Jean E. ;

Wolkenstein, Pierre ;

Viallette, Cedric ;

Gabison, Germaine ;

Pouget, Florence ;

Poli, Florence ;

Faye, Ousmane ;

Bastuji-Garin, Sylvie .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 61 (01) :51-57

[9] Risankizumab effectiveness in a recalcitrant case of hidradenitis suppurativa after anti-TNF and anti-interleukin-17 failures [J].

Caposiena Caro, Raffaele Dante ;

Pensa, Chiara ;

Lambiase, Sara ;

Candi, Eleonora ;

Bianchi, Luca .

DERMATOLOGIC THERAPY, 2021, 34 (06)

[10]

ChemoCentryx, 2020, Clinical Trial Registration NCT03852472

← 1 2 3 4 5 6 7 8 9 10 →